



: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:10PM

Reported Status

: 29/Mar/2024 02:49PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF HAEMATOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	15.7	g/dL	13-17	Spectrophotometer
PCV	45.20	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.26	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	85.9	fL	83-101	Calculated
MCH	29.8	pg	27-32	Calculated
MCHC	34.7	g/dL	31.5-34.5	Calculated
R.D.W	14.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,800	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (I	DLC)			
NEUTROPHILS	66.3	%	40-80	Electrical Impedance
LYMPHOCYTES	21.2	%	20-40	Electrical Impedance
EOSINOPHILS	6.9	%	1-6	Electrical Impedance
MONOCYTES	5.6	%	2-10	Electrical Impedance
BASOPHILS	0	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5834.4	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1865.6	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	607.2	Cells/cu.mm	20-500	Calculated
MONOCYTES	492.8	Cells/cu.mm	200-1000	Calculated
Neutrophil lymphocyte ratio (NLR)	3.13		0.78- 3.53	Calculated
PLATELET COUNT	230000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	5	mm at the end of 1 hour	0-15	Modified Westergrer
PERIPHERAL SMEAR				

RBC's are Normocytic Normochromic

WBC's Mild Eosinophilia

Platelets are Adequate

No hemoparasite seen.

Page 1 of 12



MBBS, MD (Pathology) Consultant Pathologist

SIN No:BED240087195

Dr Sneha Shah

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62,5th Floor, Ashoka RaghupathiChambers,

Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender UHID/MR No : 35 Y 9 M 15 D/M : SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF : 670816 Emp/Auth/TPA ID

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:10PM

Reported

: 29/Mar/2024 04:31PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF HAEMATOLOGY**

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FAC	TOR , WHOLE BLOOD EDT	Ά		
BLOOD GROUP TYPE	0			Microplate Hemagglutination
Rh TYPE	Positive			Microplate Hemagglutination

Dr Sneha Shah MBBS, MD (Pathology)

Consultant Pathologist SIN No:BED240087195

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

Begumpet, Hyderabad, Telangana - 500016

Address: P.No.9 & 10a, S.NO.2/64, Renata Chambers, Saras Baug Road, Vijayanagar Colony, Opp. Sanas Play Ground, Sadashiv Peth, Pune, Maharashtra

Page 2 of 12





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M : SPUN.0000047076

UHID/MR No Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816 Collected

: 29/Mar/2024 09:56AM

Received Reported : 29/Mar/2024 10:47AM : 29/Mar/2024 11:24AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	94	mg/dL	70-100	HEXOKINASE

#### **Comment:**

As ner American Diabetes Guidelines 2023

As per American Diabetes Guidennes, 2025	
Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

#### Note:

1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2

2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 3 of 12





This Apollo Special itself a spital a Parivate Lienite Ad-Sadashiv Peth Pune, Diagnostica Lab

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off: 1-10-62/62, 5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 670816 Collected

: 29/Mar/2024 09:56AM

Received Reported : 29/Mar/2024 12:10PM

Status

: 29/Mar/2024 02:01PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	98	mg/dL	70-140	HEXOKINASE

#### **Comment:**

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN) , $\nu$	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

#### **Comment:**

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.

Page 4 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:EDT240040453

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

**Regd Off:**1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:10PM

Reported Status : 29/Mar/2024 02:01PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
  - B: Homozygous Hemoglobinopathy.
  - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:EDT240040453

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off: 1-10-62/62, 5th Floor, Ashoka Raghupathi Chambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender UHID/MR No : 35 Y 9 M 15 D/M : SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 11:51AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	202	mg/dL	<200	CHO-POD
TRIGLYCERIDES	245	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	38	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	164	mg/dL	<130	Calculated
LDL CHOLESTEROL	115.37	mg/dL	<100	Calculated
VLDL CHOLESTEROL	48.92	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.35		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.45		<0.11	Calculated

#### **Comment:**

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High Very
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240
TRIGLYCERIDES	<150	150 - 199	$\begin{vmatrix} 200 - \\ 499 \end{vmatrix} \ge 500$
LDL	Optimal < 100; Near Optimal 100- 129	130 - 159	$\begin{vmatrix} 160 - \\ 189 \end{vmatrix} \ge 190$
HDL	≥ 60 °		
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219 >220
ATHEROGENIC INDEX(AIP)	<0.11	0.12 - 0.20	>0.21

#### Note:

- 1) Measurements in the same patient on different days can show physiological and analytical variations.
- 2) NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3) Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.

Page 6 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

**Regd Off:**1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M : SPUN.0000047076

UHID/MR No Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF Emp/Auth/TPA ID : 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 11:51AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

- 4) Low HDL levels are associated with coronary heart disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5) As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6) VLDL, LDL Cholesterol Non-HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dl. When

Triglycerides are more than 400 mg/dl LDL cholesterol is a direct measurement.

7) Triglycerides and HDL-cholesterol in Atherogenic index (AIP) reflect the balance between the atherogenic and protective lipoproteins. Clinical studies have shown that AIP (log (TG/HDL) & values used are in mmol/L) predicts cardiovascular risk and a useful measure of response to treatment (pharmacological intervention).

Page 7 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M : SPUN.0000047076

UHID/MR No Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816 Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported Status

: 29/Mar/2024 01:35PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
IVER FUNCTION TEST (LFT), SERUM						
BILIRUBIN, TOTAL	0.84	mg/dL	0.3–1.2	DPD		
BILIRUBIN CONJUGATED (DIRECT)	0.18	mg/dL	<0.2	DPD		
BILIRUBIN (INDIRECT)	0.66	mg/dL	0.0-1.1	Dual Wavelength		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	35.83	U/L	<50	IFCC		
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	68.3	U/L	<50	IFCC		
ALKALINE PHOSPHATASE	54.02	U/L	30-120	IFCC		
PROTEIN, TOTAL	7.88	g/dL	6.6-8.3	Biuret		
ALBUMIN	4.45	g/dL	3.5-5.2	BROMO CRESOL GREEN		
GLOBULIN	3.43	g/dL	2.0-3.5	Calculated		
A/G RATIO	1.3		0.9-2.0	Calculated		

#### **Comment:**

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

#### 1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. • Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

#### 2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated. ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited) CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID Ref Doctor : SPUNOPV62536

Emp/Auth/TPA ID

: Dr.SELF : 670816 Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 02:01PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF BIOCHEMISTRY**

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM						
CREATININE	0.94	mg/dL	0.72 – 1.18	Modified Jaffe, Kinetic		
UREA	13.91	mg/dL	17-43	GLDH, Kinetic Assay		
BLOOD UREA NITROGEN	6.5	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	5.40	mg/dL	3.5–7.2	Uricase PAP		
CALCIUM	9.50	mg/dL	8.8-10.6	Arsenazo III		
PHOSPHORUS, INORGANIC	3.80	mg/dL	2.5-4.5	Phosphomolybdate Complex		
SODIUM	139.5	mmol/L	136–146	ISE (Indirect)		
POTASSIUM	4.2	mmol/L	3.5-5.1	ISE (Indirect)		
CHLORIDE	105.67	mmol/L	101–109	ISE (Indirect)		
PROTEIN, TOTAL	7.88	g/dL	6.6-8.3	Biuret		
ALBUMIN	4.45	g/dL	3.5-5.2	BROMO CRESOL GREEN		
GLOBULIN	3.43	g/dL	2.0-3.5	Calculated		
A/G RATIO	1.3		0.9-2.0	Calculated		

Page 9 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off: 1-10-62/62, 5th Floor, Ashoka Raghupathi Chambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 11:51AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF BIOCHEMISTRY**

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	21.69	U/L	<55	IFCC

Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

Page 10 of 12





: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 670816 Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported Status : 29/Mar/2024 12:24PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF IMMUNOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSH)	, SERUM	<u>'</u>		<u>'</u>
TRI-IODOTHYRONINE (T3, TOTAL)	1.17	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	11.57	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	3.938	μIU/mL	0.34-5.60	CLIA

#### **Comment:**

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)		
First trimester	0.1 - 2.5		
Second trimester	0.2 - 3.0		
Third trimester	0.3 - 3.0		

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	<b>T4</b>	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 12





SIN No:SPL24059057

This Apollo Speciality Hospital Rariyate Lienite Rd-Sadashiv Peth Pune, Diagnostics Lab

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

**Regd Off:**1-10-62/62 ,5th Floor, Ashoka RaghupathiChambers, Begumpet, Hyderabad, Telangana - 500016





: Mr.ISHWAR KAILAS MHASKE

Age/Gender UHID/MR No : 35 Y 9 M 15 D/M : SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:22PM

Reported

: 29/Mar/2024 12:43PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### **DEPARTMENT OF CLINICAL PATHOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (	CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	<5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	>1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	2 - 3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1 - 2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

\*\*\* End Of Report \*\*\*

Page 12 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:UR2320045

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab Apollo Speciality Hospitals Private Limited

(Formely known as a Nova Speciality Hospitals Private Limited)

CIN- U85100TG2009PTC099414

Regd Off:1-10-62/62,5th Floor, Ashoka RaghupathiChambers,

Begumpet, Hyderabad, Telangana - 500016



#### APOLLO SPECTRA HOSPITALS

Opp. Sanas Sports Ground, Saras Baug, Sadashiv Peth, Pune, Maharashtra - 411 030. Ph. No: 020 6720 6500 www.apollospectra.com

Name : Mr. Ishwar Kailas Mhaske

Age: 35 Y

Sex: M

Address: 175 Yashwant Nagar HAdgaon Nanded

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:SPUN.0000047076

**OP Number:**SPUNOPV62536 **Bill No :**SPUN-OCR-10607

Date : 29.03.2024 09:36

Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2	324
	1 GAMMA GLUTAMYL TRANFERASE (GGT)	
	2 LIVER FUNCTION TEST (LFT)	
	3 GLUCOSE, FASTING	
	4 HEMOGRAM + PERIPHERAL SMEAR	
	5 COMPLETE URINE EXAMINATION	
	6 PERIPHERAL SMEAR	
	ZECG	
	8 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
	9 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	
	OH6A1c, GLYCATED HEMOGLOBIN	
1	1 X-RAY CHEST PA	
V	2 FITNESS BY GENERAL PHYSICIAN	
1	BLOOD GROUP ABO AND RH FACTOR	
14	4 LIPID PROFILE	
u	5 BODY MASS INDEX (BMI)	
1/1	OPTHAL BY GENERAL PHYSICIAN	
4	7 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	

# **CERTIFICATE OF MEDICAL FITNESS**

This is to certify that I have conducted the clinical examination

of Tshwar Maske on 29/03/24	
After reviewing the medical history and on clinical examination it has been found that he/she is	
	Tick
Medically Fit	
Fit with restrictions/recommendations	
Though following restrictions have been revealed, in my opinion, these are not impediments to the job.	
1	
2	
3	
However the employee should follow the advice/medication that has been communicated to him/her.	
Review after	
Currently Unfit.	
Review afterrecommended	
• Unfit	

General Physician Apollo Spectra Hospital Pune

This certificate is not meant for medico-legal purposes

Dr. Samrat Shah
MBBS MD
Reg No. 2021097302
Consultant internal Medicine
Apollo Speciality Hospital



Date

29/03/24

MRNO

Name

Age/Gender : Mobile No

Tshwar maske

35/19

Department:

Gen Physician Dr. Samrah

Consultant :

Reg. No

Qualification:

Consultation Timing:

SPO2 - 99'1

Pulser: 82	B.P: 114172	Resp: 20 binin	Temp: 98.66
Weight: 76Kg	Height: 167cm	BMI:	Waist Circum :

General Examination / Allergies History

Clinical Diagnosis & Management Plan

No complous

four of to goin duly

Dys lipidemia: Avoid only food forty food

T. Rosumac 10

Dr. Samrat Shah

Reg No. 2027097302
Consultant Internal Medicine
Apollo Specially Hospital
Doctor Signature

Follow up date: 3 mm 16

**Apollo Spectra Hospitals** 

Opp. Sanas Sport Ground, Saras Baug, Sadashiv Peth, Pune, Maharashtra - 411030 BOOK YOUR APPOINTMENT TODAY!

Ph.: 020 6720 6500 Fax: 020 6720 6523 www.apollospectra.com







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID Ref Doctor : SPUNOPV62536

Emp/Auth/TPA ID

: Dr.SELF

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:10PM : 29/Mar/2024 02:49PM

Reported Status

23/1VId1/2024 02.4

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF HAEMATOLOGY

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	15.7	g/dL	13-17	Spectrophotometer
PCV	45.20	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.26	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	85.9	fL	83-101	Calculated
MCH	29.8	pg	27-32	Calculated
MCHC	34.7	g/dL	31.5-34.5	Calculated
R.D.W	14.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,800	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (I	DLC)			
NEUTROPHILS	66.3	%	40-80	Electrical Impedance
LYMPHOCYTES	21.2	%	20-40	Electrical Impedance
EOSINOPHILS	6.9	%	1-6	Electrical Impedance
MONOCYTES	5.6	%	2-10	Electrical Impedance
BASOPHILS	0	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5834.4	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1865.6	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	607.2	Cells/cu.mm	20-500	Calculated
MONOCYTES	492.8	Cells/cu.mm	200-1000	Calculated
Neutrophil lymphocyte ratio (NLR)	3.13		0.78- 3.53	Calculated
PLATELET COUNT	230000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	5	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBC's are Normocytic Normochromic

WBC's Mild Eosinophilia

Platelets are Adequate

No hemoparasite seen.

Page 1 of 11



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:BED240087195







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:47AM

Reported Status

: 29/Mar/2024 11:24AM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF BIOCHEMISTRY

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	94	mg/dL	70-100	HEXOKINASE

#### Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL Interpretation			
70-100 mg/dL	Normal		
100-125 mg/dL	Prediabetes		
≥126 mg/dL	Diabetes		
<70 mg/dL	Hypoglycemia		

#### Note:

1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions

2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 2 of 11

DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:PLF02136881







: Mr.ISHWAR KAILAS MHASKE

Age/Gender UHID/MR No

: 35 Y 9 M 15 D/M

Visit ID

: SPUN.0000047076 : SPUNOPV62536

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 670816

Collected

: 29/Mar/2024 09:56AM

Received Reported : 29/Mar/2024 12:10PM : 29/Mar/2024 02:01PM

Status

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	98	mg/dL	70-140	HEXOKINASE

#### **Comment:**

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN) , WH	OLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

### Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.

3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.

Page 3 of 11



MBBS MD (Pathology) Consultant Pathologist

SIN No:EDT240040453







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No Visit ID : SPUN.0000047076 : SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:10PM

Reported

: 29/Mar/2024 02:01PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
  - B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 4 of 11



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:EDT240040453







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No Visit ID : SPUN.0000047076 : SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 11:51AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE, SERUM				
TOTAL CHOLESTEROL	202	mg/dL	<200	CHO-POD
TRIGLYCERIDES	245	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	38	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	164	mg/dL	<130	Calculated
LDL CHOLESTEROL	115.37	mg/dL	<100	Calculated
VLDL CHOLESTEROL	48.92	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.35		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.45		<0.11	Calculated

#### Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100; Near Optimal 100- 129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220
ATHEROGENIC INDEX(AIP)	< 0.11	0.12 - 0.20	>0.21	

#### Note:

- 1) Measurements in the same patient on different days can show physiological and analytical variations.
- 2) NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3) Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.

Page 5 of 11

Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No Visit ID

: SPUN.0000047076 : SPUNOPV62536

Ref Doctor

Emp/Auth/TPA ID

: Dr.SELF

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported Status

: 29/Mar/2024 11:51AM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

- 4) Low HDL levels are associated with coronary heart disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5) As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6) VLDL, LDL Cholesterol Non-HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dl. When

Triglycerides are more than 400 mg/dl LDL cholesterol is a direct measurement.

7) Triglycerides and HDL-cholesterol in Atherogenic index (AIP) reflect the balance between the atherogenic and protective lipoproteins. Clinical studies have shown that AIP (log (TG/HDL) & values used are in mmol/L) predicts cardiovascular risk and a useful measure of response to treatment (pharmacological intervention).

Page 6 of 11



Dr Sheha Shah MBBS MD (Pathology) Consultant Pathologist

SIN No:SE04680596







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID Ref Doctor : SPUNOPV62536

Emp/Auth/TPA ID

: Dr.SELF

: 670816

Collected Received : 29/Mar/2024 09:56AM

Reported

: 29/Mar/2024 10:58AM : 29/Mar/2024 01:35PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.84	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.18	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.66	mg/dL	0.0-1.1	<b>Dual Wavelength</b>
ALANINE AMINOTRANSFERASE (ALT/SGPT)	35.83	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	68.3	U/L	<50	IFCC
ALKALINE PHOSPHATASE	54.02	U/L	30-120	IFCC
PROTEIN, TOTAL	7.88	g/dL	6.6-8.3	Biuret
ALBUMIN	4.45	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.43	g/dL	2.0-3.5	Calculated
A/G RATIO	1.3		0.9-2.0	Calculated

### Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

#### 1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI . Disproportionate increase in AST, ALT compared with ALP. • Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

### 2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated. · ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 7 of 11



Dr Sheha Shah MBBS MD (Pathology) Consultant Pathologist

SIN No:SE04680596







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported Status : 29/Mar/2024 02:01PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF BIOCHEMISTRY

# ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SER	RUM		
CREATININE	0.94	mg/dL	0.72 - 1.18	Modified Jaffe, Kinetic
UREA	13.91	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	6.5	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.40	mg/dL	3.5-7.2	Uricase PAP
CALCIUM	9.50	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.80	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	139.5	mmol/L	136-146	ISE (Indirect)
POTASSIUM	4.2	mmol/L	3.5-5.1	ISE (Indirect)
CHLORIDE	105.67	mmol/L	101-109	ISE (Indirect)
PROTEIN, TOTAL	7.88	g/dL	6.6-8.3	Biuret
ALBUMIN	4.45	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	3.43	g/dL	2.0-3.5	Calculated
A/G RATIO	1.3		0.9-2.0	Calculated

Page 8 of 11



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:SE04680596







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M : SPUN.0000047076

UHID/MR No Visit ID

: SPUNOPV62536

Ref Doctor

: SPUNOPV625 : Dr.SELF

Emp/Auth/TPA ID

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 11:51AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF BIOCHEMISTRY

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	21.69	U/L	<55	IFCC

Page 9 of 11



Dr Sheha Shah MBBS MD (Pathology) Consultant Pathologist

SIN No:SE04680596







: Mr.ISHWAR KAILAS MHASKE

Age/Gender

: 35 Y 9 M 15 D/M

UHID/MR No

: SPUN.0000047076

Visit ID Ref Doctor : SPUNOPV62536

Emp/Auth/TPA ID

: Dr.SELF

: 670816

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 10:58AM

Reported

: 29/Mar/2024 12:24PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF IMMUNOLOGY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSH),	SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.17	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	11.57	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	3.938	μIU/mL	0.34-5.60	CLIA

#### Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N N Subclinical Hyperthyroidism		Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 11



DR.Sanjay Ingle M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:SPL24059057







: Mr.ISHWAR KAILAS MHASKE

Age/Gender UHID/MR No

: 35 Y 9 M 15 D/M : SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor

: 670816

Emp/Auth/TPA ID

: Dr.SELF

Collected

: 29/Mar/2024 09:56AM

Received

: 29/Mar/2024 12:22PM

Reported

: 29/Mar/2024 12:43PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF CLINICAL PATHOLOGY

#### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (	CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	<5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	>1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	<b>GLUCOSE OXIDASE</b>
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	2 - 3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1 - 2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

\*\*\* End Of Report \*\*\*

Result/s to Follow:

BLOOD GROUP ABO AND RH FACTOR

Page 11 of 11



MBBS, MD (Pathology) Consultant Pathologist

SIN No:UR2320045

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab

Ph No: 040-4904 7777 | www.apollohl.com | Email ID:enquiry@apollohl.com







: Mr.ISHWAR KAILAS MHASKE

Age/Gender UHID/MR No : 35 Y 9 M 15 D/M : SPUN.0000047076

Visit ID

: SPUNOPV62536

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 670816 Collected Received

: 29/Mar/2024 09:56AM

Reported

: 29/Mar/2024 12:10PM : 29/Mar/2024 04:31PM

Status

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

### DEPARTMENT OF HAEMATOLOGY

### ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACT	TOR , WHOLE BLOOD EDT	TA .		
BLOOD GROUP TYPE	0			Microplate Hemagglutination
Rh TYPE	Positive			Microplate Hemagglutination

Page 2 of 12



Dr Sneha Shah MBBS, MD (Pathology) Consultant Pathologist

SIN No:BED240087195

This test has been performed at Apollo Health and Lifestyle ltd- Sadashiv Peth Pune, Diagnostics Lab

Ph No: 040-4904 7777 | www.apollohl.com | Email ID:enquiry@apollohl.com



MR.ISHWAR MASKE 35Y

35 Years

MR No: Location: SPUN DODATOTO

Apollo Spectra Hospital Pune

(Swargate)

Gender:

M

Physician:

SELF

**Image Count: Arrival Time:** 

29-Mar-2024 10:03

Date of Exam: Date of Report:

29-Mar-2024 29-Mar-2024 10:17

X-RAY CHEST P.A VIEW

HISTORY: Health check up

**FINDINGS** 

Normal mediastinum.

No hilar or mediastinal lymphadenopathy.

No pericardial effusion.

Cardia is normal in size.

Right Lung field: No focal lesion. No collapse. No consolidation.

Left Lung field: No focal lesion. No collapse. No consolidation.

The apices, costo and cardiophrenic angles are free. No pleural effusion

No destructive osseous pathology is evident.

IMPRESSION:

No significant abnormality is seen.

Dr.V.Pavan Kumar.MBBS,DMRD. Consultant Radiologist Reg.No: 57017

www.apollodiagnostics.in

# **EYE REPORT**



ASH/PUN/OPTH/06/02-0216

Date: 29/03/24

Name:

Age /Sex: 35 7 1 M

Ref No.:

Complaint: No complaints

Mr. Ishwar Maske

Examination

NO DM

NO HTH

## Spectacle Rx

	Right Eye					Lef	t Eye	
	Vision	Sphere	Cyl.	Axis	Vision	Sphere	Cyl.	Axis
Distance	616	0.75			6 6	7.75		
Read	_			N6				NE
	Sphere	CYI	Axis	Vision	Sphere	CYI	Axis	Vision

Remarks:

WHL

Medications: BE colour vision Hormoll.

Trade Name	Frequency	Duration

Follow up:

Consultant:

**Apollo Spectra Hospitals** 



Company Name	PACKAGE NAME	Booking ID	EMP-NAME
Arcofemi/Mediwheel/MALE/ EMALE	ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE -2D ECHO - PAN INDIA - FY2324	UBOIE46 73	ASHOK SHANTARAM UMAPE
rcofemi/Mediwheel/MALE/ EMALE	ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324	UBOIE46 31	ISHWAR KAILAS MASKE
Arcofemi/Mediwheel/MALE/ EMALE	ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE -2D ECHO - PAN INDIA - FY2324	UBOIE46 14	SHANKAR GUPTA
	Arcofemi MediWheel Full Body Annual Plus Male Above 50 2D ECHO	bobE159 97	MR. SINGH PANKAJ KUMAR
	ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD PLUS MALE - PAN INDIA - FY2324	UBOIE43 31	SHITOLE VINOD VASANTRAO









ईश्वर कैलास मस्के Ishwar Kailas Maske जन्म तारीख/DOB: 14/06/1988 पुरुष/ MALE

Mobile No: 7498474301

5348 2700 6566

मेरा आधार, मेरी पहचान




# भारतीय विशिष्ट पहचान प्राचिकरण Unique Identification Authority of India



पत्ताः S/O कैलास मस्के, घर न १७५, यशवंत नगर हदगाव, यशवंत नगर हदगाव, हदगाव, नादंड, महाराष्ट्र - 431712

Address: S/O Kailas Maske, H No 175, Yeshawant Nagar Hadgaon, Yeshawant Nagar Hadgaon, Hadgaon, DIST: Nanded, Maharashtra - 431712



5348 2700 6566



1947 Melp@uidai.gov.in www.uidai.gov.in

